Trivascular
BackForward
Portfolio Companies
IPO And Acquisition
Representative Historical

Medical Devices and DiagnosticsBiotechnology

Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals, Inc.
Uniquely identifies, develops, and manufactures novel antibody therapeutics for autoimmune and inflammatory diseases. The company also enables partners through out-licensing of its technologies.
www.alderbio.com

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA)

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA)
Inhaled therapies for acute and intermittent conditions employing a device that rapidly delivers pure drug
www.alexza.com

Calithera Biosciences

Calithera Biosciences
Is developing activators of enzymes. The seminal discovery of allosteric activators of enzymes will allow the development of novel drug candidates. The lead program targets caspases, enzymes involved in cell death. Caspase activators will be cytotoxic drugs for use in oncology. The Company's drug development platform will allow multiple drug development partnerships.
www.calithera.com

Labcyte Inc.

Labcyte Inc.
Instrumentation using focused acoustic energy to accurately dispense very small quantities of high-value fluids for pharmaceutical research
www.labcyte.com

NeurAxon, Inc.

NeurAxon, Inc.
Developing next generation pain therapeutics
www.nrxn.com

OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals, Inc.
OncoMed Pharmaceuticals is a clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells
www.oncomed.com

ProActa, Inc.

ProActa, Inc.
Focused on the treatment of tumors by exploiting their abnormally low concentrations of oxygen (hypoxia)
www.proacta.com

PTC Therapeutics, Inc.

PTC Therapeutics, Inc.
Development of orally active small molecules that modulate post-transcriptional processes
www.ptcbio.com

Relypsa, Inc.

Relypsa, Inc.
Discovery and development of new non-absorbed polymeric drugs for important applications in cardiovascular and renal disease.
www.relypsa.com